Osaic Holdings Inc. Acquires 24,080 Shares of Boston Scientific Corporation $BSX

Osaic Holdings Inc. boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 20.0% in the second quarter, HoldingsChannel reports. The firm owned 144,745 shares of the medical equipment provider’s stock after purchasing an additional 24,080 shares during the quarter. Osaic Holdings Inc.’s holdings in Boston Scientific were worth $15,459,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC boosted its holdings in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after buying an additional 226 shares during the period. Venture Visionary Partners LLC lifted its position in Boston Scientific by 27.0% during the first quarter. Venture Visionary Partners LLC now owns 5,976 shares of the medical equipment provider’s stock worth $603,000 after acquiring an additional 1,272 shares during the last quarter. Tradition Wealth Management LLC lifted its position in Boston Scientific by 3.4% during the first quarter. Tradition Wealth Management LLC now owns 5,700 shares of the medical equipment provider’s stock worth $575,000 after acquiring an additional 190 shares during the last quarter. GM Advisory Group LLC bought a new stake in shares of Boston Scientific during the first quarter worth approximately $227,000. Finally, Dorsey & Whitney Trust CO LLC grew its position in shares of Boston Scientific by 3.4% in the first quarter. Dorsey & Whitney Trust CO LLC now owns 14,704 shares of the medical equipment provider’s stock valued at $1,483,000 after purchasing an additional 490 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BSX has been the subject of several research reports. Barclays lifted their price target on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a report on Thursday, October 2nd. Royal Bank Of Canada lifted their target price on Boston Scientific from $125.00 to $130.00 and gave the stock an “outperform” rating in a report on Wednesday. Leerink Partners boosted their target price on shares of Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Truist Financial lowered their price target on shares of Boston Scientific from $130.00 to $120.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, UBS Group reaffirmed a “buy” rating on shares of Boston Scientific in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $124.85.

Boston Scientific Stock Up 1.8%

Shares of NYSE BSX opened at $96.15 on Friday. The stock has a market capitalization of $142.54 billion, a P/E ratio of 51.42, a PEG ratio of 1.90 and a beta of 0.67. The stock’s fifty day moving average is $98.63 and its 200 day moving average is $101.34. Boston Scientific Corporation has a 52 week low of $85.98 and a 52 week high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The business had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter in the prior year, the business posted $0.63 earnings per share. Boston Scientific’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director owned 24,134 shares in the company, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 143,095 shares of company stock worth $14,228,950. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.